MedTrace Logo

Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome

NCT05255328 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this study is to assesses the clinical efficacy of oral supplementation with glutamine over 3 years.

Conditions

  • MELAS Syndrome

Interventions

DIETARY_SUPPLEMENT

Glutamine oral supplement

12-18 g /day of glutamine supplementation

Sponsors & Collaborators

  • Hospital Universitario 12 de Octubre

    lead OTHER

Principal Investigators

  • Jesús González de la Ajeja Tejera, MD, PhD · Hospital Universitario 12 Octubre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-07-15
Completion
2024-07-24

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05255328 on ClinicalTrials.gov